ALKERMES | ALKS - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 645M 69M 2026-03
Acadia Pharmaceuticals USD 0 4.12M 2024-09
ALKERMES USD 25.92M 5.03M 2026-06
Amgen USD 95.64B 94.98B 2026-06
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 63.29M 48.34M 2026-06
Bristol-Myers Squibb USD 407M 4M 2026-06
Coherus Biosciences USD 2.25M 76K 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Gilead Sciences USD 247M 7M 2026-06
Heron Therapeutics USD 600K 100K 2024-12
Ionis Pharmaceuticals USD 18M 1000K 2026-06
J&J USD 43M 25M 2026-03
Merck USD 525M 46M 2026-06
Minerva Neurosciences USD 2.31M 60K 2024-06
Nektar Therapeutics USD 7.94M 1.83M 2026-03
Neurocrine Biosciences USD 1.1M 0 2024-03
Otsuka Holdings JPY 2.21B 866M 2025-12
Ovoca Bio EUR 7K 6K 2022-06
Pfizer USD 667M 4M 2026-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Vertex Pharmaceuticals USD 3.3M 0 2025-12